Envíe este artículo por correo electrónico (Inicie sesión)
Enviar un correo electrónico al autor/a (Inicie sesión) Open Journal Systems
Lamotrigina y su relación con el síndrome de Stevens-Johnson y la necrólisis epidérmica tóxica / Lamotrigine and its relationship with Stevens-Johnson syndrome and toxic epidermal necrolysis
Resumen
Resumen
La lamotrigina es un fármaco anticonvulsivo que ha sido utilizado ampliamente para tratar la epilepsia, como estabilizador del ánimo (en casos de trastorno bipolar tipo 1) y en el manejo del dolor neuropático; se usa tanto en monoterapia como en terapia complementaria. Considerado como un medicamento relativamente nuevo, aprobado por la Food and Drug Administration en 1994, dentro de sus beneficios se encuentra un mayor margen de seguridad en comparación con otros anticonvulsivos; sin embargo, aunque en menor porcentaje, es causa de reacciones cutáneas adversas graves, como el síndrome de Stevens-Johnson y la necrólisis epidérmica tóxica. En el presente estudio se realiza una revisión de las probables vías que desencadenan esta respuesta inmunitaria de hipersensibilidad tardía.
Abstract
Lamotrigine is an antiepileptic drug that has been widely used for epilepsy, as a mood stabilizer (for type 1 bipolar disorder) and in the management of neuropathic pain, it is used both in monotherapy and in complementary therapy. Considered relatively new, approved by the Food and Drug Administration in 1994, its benefits include a greater margin of safety compared to other anticonvulsants. However, although in a lower percentage, it causes severe adverse skin reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis. A review is made about the probable pathways that trigger this delayed hypersensitivity immune response.
Palabras clave
Referencias
World Health Organization. International drug monitoring:the role of national centres. Geneva, Switzerland:World Health Organization;1972. Disponible en:https://www.who-umc.org/media/2680/who-technical-report-498.pdf
Wong S, Tham M, Goh C, Cheong H, Chan S. Spontaneous cutaneous adverse drug reaction reports —an analysis of a 10-year dataset in Singapore. Pharmacol Res Perspect. 2019;7(2):e00469.
Mustafa S, Ostrov D, Yerly D. Severe cutaneous adverse drug reactions:presentation, risk factors, and management. Curr Allergy Asthma Rep. 2018;18:26.
Goldenberg MM. Overview of drugs used for epilepsy and seizures:etiology, diagnosis, and treatment. P &T. 2010;35(7):392-415.
Rodríguez-Martín S, Martín-Merino E, Lerma V, Rodríguez-Miguel A, González O, González-Herrada C, et al. Incidence of Stevens-Johnson syndrome/toxic epidermal necrolysis among new users of different individual drugs in a European population:a case-population study. Eur J Clin Pharmacol. 2019;75:237-46.
Yi Y, Lee J, Suh E. Toxic epidermal necrolysis induced by lamotrigine treatment in a child. Korean J Pediatrs. 2014;57(3):153.
Alyahya B, Friesen M, Nauche B, LalibertéM. Acute lamotrigine overdose:a systematic review of published adult and pediatric cases. Clin Toxicol. 2018;56(2):81-9.
Alabi A, Todd A, Husband A, Reilly J. Safety profile of lamotrigine in overdose. Ther Adv Psychopharmacol. 2016;6(6):369-81.
Bassel W, Abou-Khalil. Update on antiepileptic drugs. Continuum. 2019;25(2):508-36.
Lofton AL, Klein-Schwartz W. Evaluation of lamotrigine toxicity reported to poison centers. Ann Pharmacother. 2004;38(11):1811-5.
Alvestad S, Lydersen S, Brodtkorb E. Cross-reactivity pattern of rash from current aromatic antiepileptic drugs. Epilepsy Res. 2008;80(2-3):194-200.
Wong A, Malvestiti A, Hafner M. Stevens-Johnson syndrome and toxic epidermal necrolysis:a review. Rev Assoc Med Bras. 2016;62(5):468-73.
Mittmann N, Knowles S, Koo M, Shear N, Rachlis A, Rourke S. Incidence of toxic epidermal necrolysis and Stevens-Johnson syndrome in an HIV cohort. Am J Clin Dermatol. 2012;13(1):49-54.
Harris V, Jackson C, Cooper A. Review of toxic epidermal necrolysis. Int J Mol Sci. 2016;17(12):E2135.
Mullan KA, Anderson A, Illing PT, Kwan P, Purcell AW, Mifsud NA. HLA-associated antiepileptic drug-induced cutaneous adverse reactions. HLA. 2019;93(6):417-35.
Ordoñez L, Salgueiro E, Jimeno FJ, Manso G. Spontaneous reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with antiepileptic drugs. Eur Rev Med Pharmacol Sci. 2015;19(14):2732-7.
Chen Y, Xu S, Wang Z, Zhao M, Wang H, Lu T, et al. A population pharmacokinetic–pharmacogenetic model of lamotrigine in Chinese children with epilepsy. Ther Drug Monit. 2018;40(6):730-7.
Parveen S, Javed MA. Stevens Johnson syndrome associated with lamotrigine. Pak J Med Sci. 2013;29(6):1450-2.
Wang XQ, Shi XB, Au R, Chen FS, Wang F, Lang SY. Influence of chemical structure on skin reactions induced by antiepileptic drugs —the role of the aromatic ring. Epilepsy Res. 2011;94(3):213-7.
Knowles SR, Dewhurst N, Shear NH. Anticonvulsant hypersensitivity syndrome:an update. Expert Opin Drug Saf. 2012;11(5):767-78.
Lu W, Uetrecht JP. Possible bioactivation pathways of lamotrigine. Drug Metab Dispos. 2007;35(7):1050-6.
Naisbitt DJ, Gordon SF, Pirmohamed M, Park BK. Immunological principles of adverse drug reactions:the initiation and propagation of immune responses elicited by drug treatment. Drug Saf. 2000;23(6):483-507.
Naisbitt, Farrell J, Wong G, Depta JPH, Dodd CC, Hopkins JE, et al. Characterization of drug-specific T cells in lamotrigine hypersensitivity. J Allergy Clin Immunol. 2003;111:1393-403.
Kalish RS, Askenase PW. Molecular mechanisms of CD8+T cell-mediated delayed hypersensitivity:implications for allergies, asthma, and autoimmunity. J Allergy Clin Immunol. 1999;103:192-9.
DOI: https://doi.org/10.24875/RMIMSS.M20000018
Enlaces refback
- No hay ningún enlace refback.